• 10/8/2004
  • Chen D, Daniel KG, Kuhn DJ, Kazi A, Bhuiyan M, Li LH, Wang ZG, Wan SB, Lam WH, Chan TH, Dou QP
  • FRONTIERS IN BIOSCIENCE 9: 2618-2631 Suppl. S, SEP 1 2004

The cancer-preventive effects of green tea and its main constituent (-)-epigallocatechin gallate [(-)- EGCG] are widely supported by results from epidemiological, cell culture, animal and clinical studies in the recent decade. In vitro cell culture studies show that tea polyphenols potently induce apoptotic cell death and cell cycle arrest in tumor cells but not in their normal cell counterparts. Green tea polyphenols affect several signal transduction pathways, including growth factor-mediated, the mitogen-activated protein kinase (MAPK)-dependent, and ubiquitin/proteasome degradation pathways. Epidemiological studies have suggested that the consumption of green tea lowers the risk of cancer. Various animal studies have revealed that treatment by green tea inhibits tumor incidence and multiplicity in different organ sites such as skin, lung, liver, stomach, mammary gland and colon. Phase I and II clinical trials were carried out recently to explore the anticancer effects of green tea in patients with cancer. At this time, more mechanistic research, animal studies, and clinical trials are necessary to further evaluate the role of green tea in cancer prevention.